Credit Capital Investments LLC Makes New $251,000 Investment in Insulet Corporation $PODD

Credit Capital Investments LLC acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 800 shares of the medical instruments supplier’s stock, valued at approximately $251,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of PODD. Candriam S.C.A. increased its position in shares of Insulet by 44.3% during the 2nd quarter. Candriam S.C.A. now owns 76,762 shares of the medical instruments supplier’s stock valued at $24,118,000 after purchasing an additional 23,570 shares during the last quarter. Police & Firemen s Retirement System of New Jersey increased its position in Insulet by 4.3% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,587 shares of the medical instruments supplier’s stock valued at $3,326,000 after acquiring an additional 441 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Insulet by 3.1% in the second quarter. Geode Capital Management LLC now owns 1,927,543 shares of the medical instruments supplier’s stock valued at $603,211,000 after acquiring an additional 58,309 shares during the period. denkapparat Operations GmbH boosted its stake in shares of Insulet by 16.7% during the 2nd quarter. denkapparat Operations GmbH now owns 1,118 shares of the medical instruments supplier’s stock worth $351,000 after purchasing an additional 160 shares during the period. Finally, Tobam purchased a new position in shares of Insulet during the 2nd quarter worth about $301,000.

Insulet Trading Up 3.2%

PODD opened at $336.84 on Thursday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The stock’s fifty day moving average is $324.17 and its two-hundred day moving average is $311.37. The company has a market capitalization of $23.70 billion, a P/E ratio of 102.38, a PEG ratio of 2.64 and a beta of 1.39. Insulet Corporation has a 52 week low of $230.05 and a 52 week high of $353.50.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The business had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business’s revenue was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.08 EPS. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PODD. Wolfe Research raised their price objective on shares of Insulet from $350.00 to $375.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Raymond James Financial raised their price target on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. upped their price objective on Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research note on Thursday, August 7th. Finally, Wells Fargo & Company lifted their target price on Insulet from $350.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $374.10.

Insider Transactions at Insulet

In other news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at approximately $1,200,925.44. The trade was a 16.58% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.39% of the company’s stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.